Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, et al. Gastroenterology 2021 Jun 15. pii: S0016-5085(21)03126.

Read + Share

Amedeo Smart

Independent Medical Education

Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, et al. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY. Gastroenterology 2021 Jun 15. pii: S0016-5085(21)03126.
PMID: 34144047